PYC Therapeutics Limited (ASX:PYC) shares were priced at $2.68 on 6 October 2026, up 5.10% on the day, and are up 141% over the past twelve months. The clinical-stage biotechnology company lodged its Appendix 4E preliminary financial report for the year ended 30 June 2026 on 28 August 2026, with figures in Australian dollars.

Across the broader market, the S&P/ASX 200 Health Care index [XHJ] (INDEXASX: XHJ) stood at 31,982.20, up 0.63% (+200.50 points) as of 6 October, and is down 16% over the past year. Meanwhile, the S&P/ASX 200 stood at 8,735.70, up 0.57% (+49.30 points) at the same time, and is down 2.74% over the year.

Business Model and Operational Footprint

PYC Therapeutics is a clinical-stage biotechnology company working on a new generation of RNA therapies for patients with genetic diseases. It uses a proprietary drug delivery platform designed to enhance the potency of precision medicines within the RNA therapeutic class, which the company describes as rapidly growing and commercially proven.

The company's development programs target monogenic diseases, which are caused by a single gene and which the company, citing research based on UK Biobank exome sequencing, describes as the indications with the highest likelihood of success in clinical development. PYC operates between Perth, Australia and San Francisco, California, and is led by Executive Director and Chief Executive Officer Dr Rohan Hockings. It holds a 97.1% ownership stake in Vision Pharma Limited, unchanged during the year.

Sector Dynamics

RNA therapeutics is a segment of biotechnology in which developers aim to modify disease at the level of genetic instructions. Clinical-stage companies in the segment generally record limited product Revenue and rely on income from research agreements, grants and tax incentives alongside Capital raised from investors, while they progress candidates through trials.

Monogenic disease programs are a focus because the underlying genetic cause is defined, which the company says supports the likelihood of success. Regulators in major markets have created designations for rare genetic diseases, and the pace of clinical progress, financing conditions and trial outcomes are the main factors that shape results across the sector. The company's release does not break out its programs, and refers readers to its FY2026 Annual Report for commentary.

FY26 Results Update

Income from ordinary activities rose 51.6% to $39,677,397. The loss from ordinary activities after tax attributable to owners of PYC Therapeutics Limited and its controlled entities was $43,341,565, down 13.8%. The loss for the year attributable to owners was the same amount. No dividends were paid, recommended or declared in the current or previous period, and Dividend reinvestment plans are not applicable.

Net tangible assets per ordinary security were 70.13 cents, compared with 28.56 cents in the prior period. The company noted that the prior period comparison has been calculated using post-consolidation ordinary securities. The financial statements were audited by the group's independent auditor, who issued an unqualified audit report. The company reported no associates, joint ventures or control gained or lost over entities, other than maintaining its 97.1% interest in Vision Pharma Limited.

The report is dated 28 August 2026 and signed by Dr Rohan Hockings. It was approved and authorised for release by the Board of PYC Therapeutics Limited. Detailed commentary on the results, including segment information and the sources of income, sits in the FY2026 Annual Report rather than in the preliminary financial report.

Growth Catalysts and Critical Operating Risks

The Appendix 4E itself does not set out guidance, clinical milestones or a funding outlook, so catalysts and risks are drawn from the company's described activities and the figures reported. Income growth of 51.6% and a lower loss of $43.3 million are the headline movements, and the higher net tangible assets per security of 70.13 cents are a reported Balance Sheet measure.

For a clinical-stage company, the main operating risks are inherent in drug development. These include clinical trial outcomes, regulatory decisions, Manufacturing and delivery of the drug platform, the need for further funding while the company remains loss-making, and competition from other RNA and genetic medicine developers. The company continues to report a net loss of $43,341,565, and no dividends have been paid. Its share price is up 141.78% over twelve months and moved 5.10% higher on the day.

The company also reports under Australian Accounting Standards as issued by the Australian Accounting Standards Board, the Corporations Act 2001 and other mandatory professional reporting requirements. The reporting period compared the year ended 30 June 2026 with the year ended 30 June 2025, and the results sit alongside the company's description of itself as developing treatments for genetic diseases using a platform intended to raise the potency of RNA medicines.

The release lists income and loss as the two headline results for the market. Income increased by just over half, while the loss attributable to owners narrowed by about one-seventh. Net tangible assets per security more than doubled on the post-consolidation comparison, which the company flags as the basis for the prior period figure. These are reported movements only, and the underlying drivers are not itemised in the Appendix 4E.

The Bottom Line

PYC Therapeutics reported a 51.6% rise in income to $39,677,397, a 13.8% lower loss of $43,341,565 and net tangible assets of 70.13 cents per security for FY26. Its shares are up 141.78% over the year and 5.10% on the day. The Appendix 4E is a preliminary financial report, and further detail on operations and programs is contained in the FY2026 Annual Report.